Cory Adamson, MD, PhD, MPH, MHSc, FAANS, FACS

    Associate Professor

    Emory University Department of Neurosurgery


    Neuro-Oncology Laboratory

    Chief of Neurosurgery Service

    Atlanta VA Medical Center


    • BS, Bridgewater College, 1991
    • MD, Johns Hopkins University, 1998
    • PhD, Johns Hopkins University, 1998
    • MPH, Johns Hopkins University, 1999
    • MHSc, Duke University, 2007



    • Duke Medical Center Research Mentoring Award for basis science, 2014
    • Walter E. Dandy Neurosurgical Society, 2012
    • Fellow of the American College of Surgeons, 2011
    • Duke Medical Center Master Clinician/Teacher Award nominee, 2010
    • Duke Medical Center Master Clinician/Teacher Award nominee, 2009
    • Durham VA Medical Center Executive Career Field Performance Award, 2007
    • Durham VA Medical Center Special Contribution Award, 2006
    • American Association of Neurological Surgery/Congress of Neurological Surgery Kenneth Shulman Research Award, Pediatric Section, 2006
    • American Association of Neurological Surgery Ronald L. Bittner Award, 2006
    • Southern Neurosurgical Society McCravey Basic Science Research Award, 2006
    • World Federation of Neurosurgical Societies Young Neurosurgeon Award, 2005
    • American Association of Neurological Surgery/Congress of Neurological Surgery, Preuss Resident Research Award, Tumor Section, 2005
    • Bridgewater College Young Alumnus Award (most promising alumni under 40), 2003
    • American Association of Neurological Surgery/Congress of Neurological Surgery Kenneth Shulman Research Award, Pediatric Section, 2003
    • Bridgewater College “Top 20 Alumni of All Time” Award, 2001

    Clinical Focus

    • Primary and secondary brain and spine tumors


    • American Association for Cancer Research
    • American Association of Neurological Surgeons
    • American Association of Neurological Surgeons/Congress of Neurological Surgeons Communications and Public Relations Committee
    • American Association of Neurological Surgeons/Congress of Neurological Surgeons Joint Section on Tumors
    • American Association of Neurological Surgeons International Outreach Committee
    • American Association of Neurological Surgeons Neurosurgery Research Education Foundation
    • American Association of Neurological Surgeons Young Neurosurgeon Committee
    • American Association for the Advancement of Science
    • American Medical Association
    • Congress of Neurological Surgeons
    • Duke Comprehensive Cancer Center
    • Duke Preston Robert Tisch Brain Tumor Center
    • Southern Neurosurgical Society


    Our Molecular Neuro-Oncology laboratory is interested in exploring genomic and proteomic alterations in brain tumorigenesis, as well as their prognostic and therapeutic significance. We use a myriad of in vitro and in vivo models to better characterize important pathways that may be genetically or pharmacologically targeted in order to design future therapeutic approaches. Past projects have focused on exploring specific oncogenes and migration-related genes, epigenetic regulation of gene expression, and protein association studies in malignant brain tumors. Our current laboratory effort has four primary research projects:

    • 1) defining protein associations and signaling networks that underlie specific tumor cell characteristics including glioma cell migration, cytoskeletal rearrangements, extracellular matrix interactions, metabolism, and glioma stem cells
    • 2) evaluating ways to more specifically target glioma cells with fluorescent probes that may aid in surgical resections
    • 3) comparing genomic and proteomic signatures between Western and African society meningiomas to better understand the differences in these patient populations
    • 4) utilizing local institutional and large national clinical databases to better characterize various brain tumor patients and responses to treatments.


    • Kang JH, Healy P, Herndon J, Lipp ES, Peters KB, Vlahovic G, Sampson JH, Friedman HS, Friedman AH, Desjardins A, Adamson DC. Levetiracetam’s Effectiveness in Preventing Postoperative Seizures in Malignant Glioma: Still a debate. Submitted June, 2014.
    • Lin JB, Fee BE, Rivas, M, Adamson DC. Modulation of U87 Glioma Stem Cells Using a Small Molecule Wnt Inhibitor. Submitted June, 2014.
    • Elsamadicy AA, Babu R, Kirkpatrick J, Adamson DC. Improved survival for radiation-induced malignant gliomas. World J of Neusosurg, Accepted May, 2014.
    • Hatef J, Michael A, Adamson DC. Traumatic Head Injury Triage and Early Treatment Guidelines in Veterans. Military Med, Submitted May, 2014.
    • Babu R, Di C, McLendon RE, Adamson DC. Epidermal Growth Factor Targeted Fluorescein for Glioblastoma Boundary Delineation: A Novel Fluorophore with Superior Specificity. Neurosurg, Submitted 2014.
    • Prasanna M, Di C, Lin JB, Rivas MV, Fee BE, Adamson DC. Glioblastoma epigenetics. Submitted May 2014.
    • Prasanna M, Di C, Lin JB, Rivas MV, Fee BE, Adamson DC. AJAP1 reduces migratory behavior in glioma cells through a FOXM1-mediated interaction with E-Cadherin. Submitted May 2014.
    • Di C, Mladkova N, Fu J, McLendon RE, Bigner DD, Adamson DC. Loss of AJAP1 expression increases invasion and migration of glioblastoma tumor cells and correlates with worse survival. Clin Canc Res. Submitted 2014.
    • Sharma R, Babu R, Manhas A, Grant GA, Adamson DC. Prognostic factors in pediatric malignant brainstem gliomas: a population-based analysis of cases with tissue diagnosis. Submitted 2013.
    • Kang JH, Adamson DC. Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opin. Investig. Drugs, Early Online:1-19, May 2015.

    For a complete listing of Dr. Adamson’s publications and other works, please click the Google Scholar logo.

    Google Scholar